JP6791750B2 - 多重化アッセイを行うための改良された方法 - Google Patents
多重化アッセイを行うための改良された方法 Download PDFInfo
- Publication number
- JP6791750B2 JP6791750B2 JP2016501106A JP2016501106A JP6791750B2 JP 6791750 B2 JP6791750 B2 JP 6791750B2 JP 2016501106 A JP2016501106 A JP 2016501106A JP 2016501106 A JP2016501106 A JP 2016501106A JP 6791750 B2 JP6791750 B2 JP 6791750B2
- Authority
- JP
- Japan
- Prior art keywords
- binding
- target substance
- target
- linking agent
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 99
- 238000003556 assay Methods 0.000 title description 137
- 238000009739 binding Methods 0.000 claims description 752
- 230000027455 binding Effects 0.000 claims description 746
- 239000003153 chemical reaction reagent Substances 0.000 claims description 484
- 239000013076 target substance Substances 0.000 claims description 483
- 108091034117 Oligonucleotide Proteins 0.000 claims description 304
- 230000000295 complement effect Effects 0.000 claims description 289
- 239000003795 chemical substances by application Substances 0.000 claims description 260
- 239000000126 substance Substances 0.000 claims description 191
- 238000004458 analytical method Methods 0.000 claims description 144
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 123
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 95
- 238000001514 detection method Methods 0.000 claims description 83
- 229960002685 biotin Drugs 0.000 claims description 63
- 239000011616 biotin Substances 0.000 claims description 63
- 235000020958 biotin Nutrition 0.000 claims description 62
- 108010090804 Streptavidin Proteins 0.000 claims description 60
- 239000003431 cross linking reagent Substances 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 39
- 108090001008 Avidin Proteins 0.000 claims description 29
- 230000009260 cross reactivity Effects 0.000 claims description 25
- 238000005259 measurement Methods 0.000 claims description 24
- 238000000159 protein binding assay Methods 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- 239000013077 target material Substances 0.000 claims description 21
- 230000009871 nonspecific binding Effects 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007822 coupling agent Substances 0.000 claims description 6
- 239000012491 analyte Substances 0.000 claims description 3
- 238000012875 competitive assay Methods 0.000 claims description 2
- 238000012493 sandwich binding assay Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 93
- 239000000203 mixture Substances 0.000 description 52
- 239000002245 particle Substances 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 239000007787 solid Substances 0.000 description 25
- 239000002585 base Substances 0.000 description 24
- 239000003446 ligand Substances 0.000 description 23
- 241000700605 Viruses Species 0.000 description 20
- 239000003085 diluting agent Substances 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 239000011859 microparticle Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000002788 anti-peptide Effects 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- -1 alkin group Chemical group 0.000 description 10
- 238000004020 luminiscence type Methods 0.000 description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000002966 oligonucleotide array Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 239000000138 intercalating agent Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000005389 magnetism Effects 0.000 description 4
- 239000012898 sample dilution Substances 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000002967 competitive immunoassay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940047650 haemophilus influenzae Drugs 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000712891 Arenavirus Species 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241001619326 Cephalosporium Species 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- NGNQZCDZXSOVQU-UHFFFAOYSA-N 8,16,18,26,34,36-hexahydroxyhentetracontane-2,6,10,14,24,28,32-heptone Chemical compound CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCC(C)=O NGNQZCDZXSOVQU-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 101100460146 Arabidopsis thaliana NEET gene Proteins 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
- DRSFVGQMPYTGJY-GNSLJVCWSA-N Deprodone propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DRSFVGQMPYTGJY-GNSLJVCWSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000574013 Homo sapiens Pre-mRNA-processing factor 40 homolog A Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028780 Nasal ulcer Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100025822 Pre-mRNA-processing factor 40 homolog A Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50853—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates with covers or lids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/021—Identification, e.g. bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0609—Holders integrated in container to position an object
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
それぞれの開示を参照によってその全体として本明細書に組み入れる、それぞれ2013年3月11日に出願した米国特許仮出願第61/775860号、2013年3月13日に出願した第61/778727号を参照する。
本発明は、アメリカ国立癌研究所により授与された5RCA130391−04のもとに連邦政府の支援により行われた。米国政府は、本発明における特定の権利を有する。
1つまたは複数の工程で、以下の成分:対象の第1の分析対象物質および対象の第2の分析対象物質を含む試料、第1の結合ドメイン上に固定化された第1の標的物質、連結剤に接続された、第1の標的物質の結合相手である第1の標的物質相補体、補助連結剤に接続された、第1の分析対象物質の結合相手である第1の結合試薬、第2の結合ドメイン上に固定化された第2の標的物質、連結剤に接続された、第2の標的物質の結合相手である第2の標的物質相補体、補助連結剤に接続された、第2の分析対象物質の結合相手である第2の結合試薬ならびに場合により架橋剤の少なくとも2つのコピーを混ぜ合わせる工程であって、架橋剤が除外される場合には、各連結剤が補助連結剤の結合相手であり、架橋剤が含められる場合には、架橋剤が連結剤の1つに対する第1の結合部位および補助連結剤の1つに対するさらなる結合部位を有する、工程と、
第1の標的物質、第1の標的物質相補体、第1の結合試薬および第1の分析対象物質を含む第1の結合ドメイン上の第1の結合複合体ならびに第2の標的物質、第2の標的物質相補体、第2の結合試薬および第2の分析対象物質を含む第2の結合ドメイン上の第2の結合複合体を形成する工程と、
第1および第2の結合ドメイン上の第1および第2の分析対象物質の量をそれぞれ測定する工程。
(b)第1および第2の結合試薬複合体を、第1の分析対象物質または第1の分析対象物質を含む複合体に結合する第1の検出試薬および第2の分析対象物質または第2の分析対象物質を含む複合体に結合する第2の検出試薬を含む複数の検出試薬と接触させる工程と、(c)2つ以上の結合ドメインに結合した第1および第2の分析対象物質の量を測定する工程。
(a)1つまたは複数の工程で、以下の成分を混ぜ合わせる工程:
(i)対象の第1の分析対象物質および対象の第2の分析対象物質を含む試料、
(ii)第1の結合ドメイン上に固定化された第1の標的物質、
(iii)連結剤に接続され、第1の標的物質の結合相手である、第1の標的物質相補体、
(iv)補助連結剤に接続され、第1の分析対象物質の結合相手である、第1の結合試薬、
(v)第2の結合ドメイン上に固定化された第2の標的物質、
(vi)連結剤に接続され、第2の標的物質の結合相手である、第2の標的物質相補体、
(vii)補助連結剤に接続され、第2の分析対象物質の結合相手である、第2の結合試薬、および
(viii)場合により、架橋剤の少なくとも2つのコピー、ここで、架橋剤が除外される場合には、各連結剤は、補助連結剤の結合相手であり、または架橋剤が含められる場合には、架橋剤は、連結剤の1つに対する第1の結合部位および補助連結剤の1つに対するさらなる結合部位を有する;
(b)以下のものを形成する工程
(i)第1の標的物質、第1の標的物質相補体、第1の結合試薬および第1の分析対象物質を含む第1の結合ドメイン上の第1の結合複合体、ならびに
(ii)第2の標的物質、第2の標的物質相補体、第2の結合試薬および第2の分析対象物質を含む第2の結合ドメイン上の第2の結合複合体、
ならびに
(c)それぞれ第1および第2の結合ドメイン上の第1および第2の分析対象物質の量を測定する工程。
本発明の方法により分析することができる試料の例は、食物試料(食物抽出物、食物ホモジネート、飲料等を含む)、環境試料(例えば、土壌試料、環境汚泥、収集環境エアゾール、環境ワイプ、ろ過水等)、工業試料(例えば、出発物質、工業生産工程からの製品または中間体)、ヒト臨床試料、獣医学試料および生体起源の他の試料を含むが、これらに限定されない。分析することができる生体試料は、糞便、粘膜スワブ、生理液および/または細胞の懸濁液を含む試料を含むが、これらに限定されない。生体試料の特定の例は、血液、血清、血漿、糞便、粘膜スワブ、組織吸引物、組織ホモジネート、細胞培養および細胞培養上清(真核および原核細胞の培養を含む)、尿、唾液、痰ならびに脳脊髄液を含む。
結合アッセイの分野の技術者は、本発明の方法に用いることができる結合剤および随伴(companion)結合相手の範囲を容易に理解するであろう。そのような対の非限定的なリストは、(いずれかの順序で)オリゴヌクレオチドおよび相補体、受容体/リガンド対、抗体/抗原、天然または合成受容体/リガンド対、アミンおよびカルボニル化合物(すなわち、シッフ塩基の形成による結合)、ハプテン/抗体対、抗原/抗体対、エピトープ/抗体対、ミニトープ/抗体対、アプタマー/標的分子対、ハイブリダイゼーションパートナーおよびインターカレーター/標的分子対を含む。
結合試薬は、直接的または間接的に、互いおよび/または固相へのそれらの結合を可能にする成分に連結される。これらの成分は、本明細書では標的物質および連結剤と呼ぶ。本明細書で用いているように、標的物質およびそれらの相補体は、結合試薬を表面または担体に接着するために用いられるが、連結剤および補助連結剤は、もし架橋剤を用いる場合には架橋剤を介して直接的または間接的に、結合試薬を標的物質に結合させるために用いられる。
多種多様な固相が、結合アッセイの分野の通常の固相を含む本発明の方法に用いるのに適している。固相は、ポリマー(例えば、ポリスチレンおよびポリプロピレン)、セラミック、ガラス、複合材料(例えば、炭素ベースのインクのような炭素−ポリマー複合材料)を含む多種の材料により製造することができる。適切な固相は、アッセイ容器(例えば、試験管、キュベット、フローセル、カートリッジ、多ウエルプレートにおけるウエル等)の内面、スライド、アッセイチップ(遺伝子またはタンパク質チップ測定に用いられるものなど)などの巨視的物体の表面、ピンまたはプローブ、ビーズ、ろ過媒体、側方流動媒体(例えば、側方流動試験ストリップに用いられるろ過膜)等を含む。
本発明の方法は、様々なアッセイ装置および/または方式に用いることができる。アッセイ装置は、例えば、アッセイが進行するときに加えられるまたはアッセイモジュールのウエル、チャンバーもしくはアッセイ領域に事前に装入されるアッセイ試薬(標的物質または他の結合試薬を含み得る)を有するアッセイプレート、カートリッジ、多ウエルプレート、反応容器、試験管、キュベット、フローセル、アッセイチップ、側方流動装置等のようなアッセイモジュールを含み得る。これらの装置は、特異的結合アッセイ、例えば、免疫測定法または免疫クロマトグラフ測定法の様々なアッセイ方式を用い得る。例示のアッセイ装置および方式が、本明細書において以下で述べられる。特定の実施形態において、本発明の方法は、乾燥状態で保存されているアッセイ試薬を用い得るものであり、アッセイ装置/キットは、アッセイ試薬を乾燥状態に維持するための乾燥材料をさらに含みまたは乾燥材料とともに供給され得る。アッセイ試薬を事前に装入したアッセイ装置は、保存中の優れた安定性を維持すると同時にアッセイ測定の迅速性を著しく改良し、その複雑さを低減し得る。乾燥アッセイ試薬は、乾燥し、アッセイに使用する前に再構成することができる。これらは、結合アッセイに有用な結合試薬、酵素、酵素基質、指示染料および対象の分析対象物質を検出するために用いることができる他の反応性化合物を含むが、これらに限定されていない。アッセイ試薬はまた、ブロッキング剤、安定化剤、洗剤、塩、pH緩衝剤、保存剤等を含むが、これらに限定されない、検出の機構に直接関与しないが、アッセイにおいて補助的役割を果たす物質を含み得る。試薬は、遊離形で、あるいはアッセイモジュールにおけるコンパートメント(例えば、チャンバー、チェンネル、フローセル、ウエル等)の表面またはコロイド、ビーズもしくは他の粒子状担体の表面を含む固相上に担持されて存在し得る。
本発明の方法は、分析対象物質の量を測定する、特に、固相に結合した分析対象物質の量を測定する様々な方法とともに用いることができる。用いることができる技術は、培養ベースのアッセイ、結合アッセイ(凝集試験、免疫測定法、核酸ハイブリダイゼーションアッセイ等を含む)、酵素アッセイ、比色分析等のような当技術分野で公知の技術を含むが、これらに限定されない。他の適切な技術は、当技術分野の平均的技術者には直ちに明らかであろう。一部の測定技術は、測定を目視検査により行うことを可能にし、他の測定技術は、測定を行うための機器を必要としまたはその使用が有効であり得る。
1つの実施形態において、本発明は、それぞれが第1および第2の標的物質、例えば、第1および第2のオリゴヌクレオチドを含む複数の別個の結合ドメインを含む、表面、例えば、多ウエルプレートまたは複数の粒子ならびに別個のバイアル、容器またはコンパートメント入りの、連結剤に結合した第1のオリゴヌクレオチド相補体および第2の連結剤に結合した第2のオリゴヌクレオチド相補体を含むキットを提供する。好ましい実施形態において、(i)第1の標的物質および第1の標的物質相補体は、標的物質の第1の対を構成し、(ii)第2の標的物質および第2の標的物質相補体は、標的物質の第2の対を構成する。好ましくは、標的物質の第1および第2の対は、表1に示す配列の対から選択される、それぞれオリゴヌクレオチドの第1および第2の対を含む。
(a)前記複数の分析対象物質における第1の分析対象物質に対して特異的な第1の結合試薬および前記第1のオリゴヌクレオチドを含む第1の結合試薬複合体を形成する工程であって、前記第1の結合試薬が連結剤に結合し、前記第1のオリゴヌクレオチドが補助連結剤に結合し、前記第1の結合試薬複合体が前記連結剤と前記補助連結剤との間の反応により形成される、工程と、
(b)前記複数の分析対象物質における第1の分析対象物質に対して特異的な第2の結合試薬および前記第2のオリゴヌクレオチドを含む第2の結合試薬複合体を形成する工程であって、前記第2の結合試薬が第2の連結剤に結合し、前記第2のオリゴヌクレオチドが第2の補助連結剤に結合し、前記第2の結合試薬複合体が前記第2の連結剤と前記第2の補助連結剤との間の反応により形成される、工程と、
(c)第1および第2の結合試薬複合体を、それぞれがそれぞれ第1のオリゴヌクレオチド相補体および第2のオリゴヌクレオチド相補体に連結された2つ以上の結合ドメインと、前記第1のオリゴヌクレオチドを前記第1のオリゴヌクレオチド相補体に、前記第2のオリゴヌクレオチドを前記第2のオリゴヌクレオチド相補体に結合させるのに十分な条件下で、混合する工程と、
(d)前記複数の分析対象物質を含む試料を工程(c)で形成された混合物と混合する工程と、
(e)複数のさらなる結合試薬を工程(d)で形成された混合物に加える工程であって、前記複数のさらなる結合試薬が(i)第1の分析対象物質および/または第1の結合試薬−第1の分析対象物質複合体に対して特異的な第1の検出試薬ならびに(ii)第2の分析対象物質および/または第2の結合試薬−第2の分析対象物質複合体に対して特異的な第2の検出試薬を含む、工程と、
(f)前記結合ドメインに結合した第1および第2の分析対象物質の量を測定する工程。
直接アッセイ用の多ウエルプレートの調製および使用の手順を図2に例示する。実験レイアウト、すなわち、どのオリゴヌクレオチド配列を多ウエルアッセイプレートのどの結合ドメインに配置したかを示した。多ウエルアッセイプレートは、Meso Scale Diagnostics,LLC(Rockville、MD)の一部門であるMeso Scale Discoveryから入手した。それぞれの個別のオリゴヌクレオチド配列相補体の希釈標準溶液(550μL)は、配列相補体の保存溶液をDiluent 100で約50倍希釈することによって調製した(オリゴヌクレオチド配列相補体の保存溶液およびDiluent 100は、Meso Scale Discoveryから入手できる)。
オリゴヌクレオチド−SAコンジュゲートを用いた間接アッセイ用の多ウエルプレートの調製および使用の手順を図9(a)〜(c)に例示する。多ウエルアッセイプレートの実験レイアウトを実施例1と同様に示した。ストレプトアビジン(SA)に結合したそれぞれの個別のオリゴヌクレオチド配列相補体の希釈標準溶液(550μL)は、配列相補体の保存溶液をDiluent 100で約50倍希釈することによって調製した(オリゴヌクレオチド配列相補体の保存溶液およびDiluent 100は、Meso Scale Discoveryから入手できる)。ビオチニル化抗体の溶液をオリゴヌクレオチド配列相補体の所望の希釈標準溶液に加えて、一組の個別のビオチニル化捕捉抗体/オリゴヌクレオチド−SA混合物を調製した。混合物中のビオチニル化抗体の濃度は、約5〜30μg/mLの範囲にあった。混合物を室温で30〜45分間緩やかに混合した。50μLのビオチン溶液(Meso Scale Discovery)(約3倍過剰のビオチン)をそれぞれの個別のビオチニル化抗体/オリゴヌクレオチド相補体混合物に加え、この混合物を室温で10〜15分間緩やかに混合した。等量(550μL)の個別のビオチニル化抗体/オリゴヌクレオチド相補体を混ぜ合わせ、溶液の総容積を、コンジュゲーション緩衝液(pH7.4の0.1M EDTAを含むPBS)の添加により5500μLに調整した。
ビオチニル化捕捉抗体、ニートストレプトアビジンおよびビオチニル化オリゴヌクレオチドを用いた間接アッセイ用の多ウエルプレートの調製および使用の手順を図10(a)〜(c)に例示する。多ウエルアッセイプレートの実験レイアウトを実施例1と同様に示した。ストレプトアビジン(SA)に結合したそれぞれの個別のオリゴヌクレオチド配列相補体の過剰の希釈標準溶液(550μL)は、配列相補体の保存溶液をDiluent 100で約50倍希釈することによって調製した(オリゴヌクレオチド配列相補体の保存溶液およびDiluent 100は、Meso Scale Discoveryから入手できる)。ビオチニル化抗体の溶液をオリゴヌクレオチド配列相補体の所望の希釈標準溶液に加えて、一組の個別のビオチニル化捕捉抗体/オリゴヌクレオチド−SA混合物を調製した。混合物中のビオチニル化抗体の濃度は、約5〜30μg/mLの範囲にあった。混合物を室温で30〜45分間緩やかに混合した。50μLのビオチン溶液(Meso Scale Discovery)(約3倍過剰のビオチン)をそれぞれの個別のビオチニル化抗体/オリゴヌクレオチド相補体混合物に加え、この混合物を室温で10〜15分間緩やかに混合した。等量(550μL)の個別のビオチニル化抗体/オリゴヌクレオチド相補体を混ぜ合わせ、溶液の総容積を、コンジュゲーション緩衝液(Meso Scale Discoveryから入手できる)の添加により5500μLに調整した。
7プレックスサイトカインBパネル(IL−8、hTNF−a、hEotaxin−3、h−Eotaxin、hMCP−1、HIP−10およびhMIP−1a)を実施例1、2および3で述べたアッセイ方式、すなわち、直接、オリゴヌクレオチド−SAコンジュゲートを用いた間接およびニートSA/ビオチニル化オリゴヌクレオチドを用いた間接アッセイ方式で試験した。アッセイのLOD値は、25標準偏差を仮定する8ポイント校正曲線から推定した。結果を図11(a)〜(g)に示す。直接および間接アッセイ方式のLOD値を、すべての試験したアッセイについて標準受動吸着および免疫測定法で観測されたLOD値と比較している。ニートSAを用いた間接アプローチは、LOD値のかなりの広がりを示し、一部のアッセイIL−8およびhIP−10は、残りのアッセイ方式と比較してより高いLOD値を示したが、エオタキシンMIP−10は、より低いLOD値を示した。
Claims (10)
- 対象の複数の分析対象物質の多重化結合アッセイを行う方法であって、
(a)1つまたは複数の工程で、以下の成分を混ぜ合わせる工程:
(i)対象の第1の分析対象物質および対象の第2の分析対象物質を含む複数の分析対象物質を含む試料、
(ii)第1の結合ドメイン上に固定化された第1の標的物質、ここで第1の標的物質はオリゴヌクレオチドを含み、
(iii)第1の連結剤に接続され、第1の標的物質の結合相手である、第1の標的物質相補体、ここで第1の標的物質相補体は、第1のオリゴヌクレオチド対を形成する第1の標的物質オリゴヌクレオチドに相補的なオリゴヌクレオチドを含み、
(iv)第1の補助連結剤に接続され、第1の分析対象物質の結合相手である、第1の結合試薬、
(v)第2の結合ドメイン上に固定化された第2の標的物質、ここで第2の標的物質はオリゴヌクレオチドを含み、
(vi)第2の連結剤に接続され、第2の標的物質の結合相手である、第2の標的物質相補体、ここで第2の標的物質相補体は、第1のオリゴヌクレオチド対とは異なる第2のオリゴヌクレオチド対を形成する第2の標的物質オリゴヌクレオチドに相補的なオリゴヌクレオチドを含み、
(vii)第2の補助連結剤に接続され、第2の分析対象物質の結合相手である、第2の結合試薬、および
(viii)場合により、架橋剤の少なくとも2つのコピー、
ここで、架橋剤が除外される場合には、a)第1および第2の連結剤はビオチンであり、第1および第2の補助連結剤はストレプトアビジンまたはアビジンであるか、またはb)第1および第2の連結剤はストレプトアビジンまたはアビジンであり、第1および第2の補助連結剤はビオチンであり、または
架橋剤が含められる場合には、架橋剤はストレプトアビジンまたはアビジンであり、第1および第2の連結剤ならびに第1および第2の補助連結剤は各々ビオチンである;
(b)以下のものを形成する工程
(i)第1の標的物質、第1の標的物質相補体、第1の結合試薬および第1の分析対象物
質を含む第1の結合ドメイン上の第1の結合複合体、ならびに
(ii)第2の標的物質、第2の標的物質相補体、第2の結合試薬および第2の分析対象物質を含む第2の結合ドメイン上の第2の結合複合体、
ならびに
(c)それぞれ第1および第2の結合ドメイン上の第1および第2の分析対象物質の量を測定する工程、ここで工程(a)において混ぜ合わされた成分が第1の分析対象物質に結合する第1の検出試薬および第2の分析対象物質に結合する第2の検出試薬をさらに含み、工程(b)において形成された第1および第2の複合体がそれぞれ第1および第2の検出試薬をさらに含み、該測定する工程は、第1および第2の検出試薬の存在を測定する工程をさらに含み、第1の検出試薬は第1の検出可能な標識を含み、第1の検出試薬は抗体を含み、第2の検出試薬は第2の検出可能な標識を含み、第2の検出試薬は抗体を含む、を含む前記方法。 - 試料がさらなる分析対象物質をさらに含み、混ぜ合わせ工程(a)が
1つまたは複数の工程で、(ix)さらなる結合ドメイン上に固定化されたさらなる標的物質、さらなる連結剤に接続されたさらなる標的物質相補体、およびさらなる補助連結剤に接続されたさらなる結合試薬、ならびに(x)さらなる標的物質、さらなる標的物質相補体、さらなる結合試薬およびさらなる分析対象物質を含むさらなる結合ドメイン上のさらなる結合複合体を混ぜ合わせる工程をさらに含み、
ここで、架橋剤が除外される場合には、a)さらなる連結剤はビオチンであり、さらなる補助連結剤はストレプトアビジンまたはアビジンであるか、またはb)さらなる連結剤はストレプトアビジンまたはアビジンであり、さらなる補助連結剤はビオチンであり、または
架橋剤が含められる場合には、架橋剤はストレプトアビジンまたはアビジンであり、さらなる連結剤およびさらなる補助連結剤は各々ビオチンである;
形成工程(b)が(iii)さらなる標的物質、さらなる標的物質相補体、さらなる結合試薬およびさらなる分析対象物質を含むさらなる結合ドメイン上のさらなる結合複合体を形成する工程をさらに含み、
工程(c)における測定がさらなる結合ドメイン上のさらなる分析対象物質の量を測定する工程をさらに含む、請求項1に記載の方法。 - 第1の標的物質相補体および第1の結合試薬を、第1の連結剤と第1の補助連結剤との間の結合相互作用により連結された第1の標的物質相補体および第1の結合試薬を含む事前に結合させた第1の標的複合体として準備し、
第2の標的物質相補体および第2の結合試薬を、第2の連結剤と第2の補助連結剤との間の結合相互作用により連結された第2の標的物質相補体および第2の結合試薬を含む事前に結合させた第2の標的複合体として準備する、
請求項1に記載の方法。 - 工程(a)が
第1の容積の液体中で、前記第1の標的物質相補体、前記第1の結合試薬および、用いる場合、前記架橋剤を混ぜ合わせ、前記第1の標的物質相補体と前記第1の結合試薬をそれらの結合した第1の連結剤および第1の補助連結剤を介して連結して、第1の標的複合体を形成し、
第2の容積の液体中で、前記第2の標的物質相補体、前記第2の結合試薬および、用いる場合、前記架橋剤を混ぜ合わせ、前記第2の標的物質相補体と前記第2の結合試薬をそれらの結合した第2の連結剤および第2の補助連結剤を介して連結して、第2の標的複合体を形成する
工程を含む、請求項1に記載の方法。 - 第1および第2の結合試薬が抗体である、請求項1に記載の方法。
- サンドイッチ結合アッセイを行うことを含む、請求項1に記載の方法。
- 競合的結合アッセイを行なうことを含む、請求項1に記載の方法。
- 少なくとも10個の結合ドメインが存在する、請求項1または2に記載の方法。
- 非特異的結合ドメインに配置されている結合試薬に対する対象の分析対象物質の観測される交差反応性が当分析対象物質に割り当てられた結合ドメインにおける結合試薬への結合の0.5%未満である、請求項1または2に記載の方法。
- 非特異的結合ドメインに配置されている結合試薬に対する対象の分析対象物質の観測される交差反応性が当分析対象物質に割り当てられた結合ドメインにおける結合試薬への結合の0.1%未満である、請求項1または2に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361775860P | 2013-03-11 | 2013-03-11 | |
US61/775,860 | 2013-03-11 | ||
US201361778727P | 2013-03-13 | 2013-03-13 | |
US61/778,727 | 2013-03-13 | ||
PCT/US2014/022948 WO2014164594A1 (en) | 2013-03-11 | 2014-03-11 | Improved methods for conducting multiplexed assays |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016511417A JP2016511417A (ja) | 2016-04-14 |
JP2016511417A5 JP2016511417A5 (ja) | 2017-03-09 |
JP6791750B2 true JP6791750B2 (ja) | 2020-11-25 |
Family
ID=51488514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501106A Active JP6791750B2 (ja) | 2013-03-11 | 2014-03-11 | 多重化アッセイを行うための改良された方法 |
Country Status (11)
Country | Link |
---|---|
US (11) | US10189023B2 (ja) |
EP (2) | EP2972353B1 (ja) |
JP (1) | JP6791750B2 (ja) |
KR (3) | KR20220147717A (ja) |
CN (2) | CN110286215A (ja) |
AU (3) | AU2014249190C1 (ja) |
CA (2) | CA3153763A1 (ja) |
DK (1) | DK2972353T3 (ja) |
ES (1) | ES2942031T3 (ja) |
HK (1) | HK1213048A1 (ja) |
WO (1) | WO2014164594A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3153763A1 (en) * | 2013-03-11 | 2014-10-09 | Meso Scale Technologies, Llc. | Improved methods for conducting multiplexed assays |
EP3696277B1 (en) | 2013-07-30 | 2023-01-25 | President and Fellows of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
WO2016164477A1 (en) | 2015-04-06 | 2016-10-13 | Meso Scale Technologies, Llc. | High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus |
JP7051206B2 (ja) * | 2015-04-22 | 2022-04-11 | バークレー ライツ,インコーポレイテッド | マイクロ流体細胞培養 |
CN112881728A (zh) | 2015-07-15 | 2021-06-01 | Hycor生物医学有限责任公司 | 可定制仪器 |
KR102557419B1 (ko) * | 2015-08-07 | 2023-07-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 단백질-단백질 상호작용의 초해상도 영상화 |
US10799865B2 (en) | 2015-10-27 | 2020-10-13 | Berkeley Lights, Inc. | Microfluidic apparatus having an optimized electrowetting surface and related systems and methods |
USD882818S1 (en) * | 2016-03-18 | 2020-04-28 | Meso Scale Technologies, Llc. | Reagent rack |
USD889685S1 (en) * | 2016-03-18 | 2020-07-07 | Meso Scale Technologies, Llc. | Reagent rack cover |
SG11201809539RA (en) | 2016-05-26 | 2018-12-28 | Berkeley Lights Inc | Covalently modified surfaces, kits, and methods of preparation and use |
EP3488239A1 (en) * | 2016-07-22 | 2019-05-29 | Verily Life Sciences LLC | Quantitative massively parallel proteomics |
WO2018025046A2 (en) * | 2016-08-05 | 2018-02-08 | Nn Scientific Limited | Device |
US10618717B2 (en) * | 2017-07-31 | 2020-04-14 | Argos Technology, Inc. | Cryogenic storage box |
WO2019069372A1 (ja) * | 2017-10-03 | 2019-04-11 | 株式会社ニコン | 検出対象の測定方法、捕捉プローブ固定化担体、検出キット、及び流体デバイス |
CA3087624A1 (en) * | 2018-01-05 | 2019-07-11 | Quotient Suisse Sa | Self-assembling diagnostic array platform |
EP4310184A3 (en) | 2018-02-23 | 2024-05-01 | Meso Scale Technologies, LLC. | Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule |
WO2019222708A2 (en) | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
US10936163B2 (en) | 2018-07-17 | 2021-03-02 | Methodical Mind, Llc. | Graphical user interface system |
US20210382043A1 (en) | 2018-10-23 | 2021-12-09 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
WO2020099533A1 (en) * | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
EP3957995A1 (en) | 2018-11-19 | 2022-02-23 | Bioaster | Methods and reagents for multiplex binding experiments |
GB2579810B (en) * | 2018-12-14 | 2023-04-26 | Aeirtec Ltd | Assay Analysis |
WO2020180645A1 (en) | 2019-03-01 | 2020-09-10 | Meso Scale Technologies, Llc. | Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same |
SG11202111871WA (en) | 2019-05-03 | 2021-11-29 | Meso Scale Technologies Llc | Kits for detecting one or more target nucleic acid analytes in a sample and methods of making and using the same |
AU2020380282A1 (en) | 2019-11-05 | 2022-05-26 | Meso Scale Technologies, Llc. | Methods and kits for quantitating radiation exposure |
WO2021108666A2 (en) | 2019-11-26 | 2021-06-03 | Meso Scale Technologies, Llc. | Methods and kits for detecting autoimmune diseases |
WO2021222830A1 (en) | 2020-05-01 | 2021-11-04 | Meso Scale Technologies, Llc. | Viral serology assays |
US11740240B2 (en) * | 2020-07-20 | 2023-08-29 | Bio-Rad Laboratories, Inc. | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor |
WO2022032194A1 (en) | 2020-08-06 | 2022-02-10 | Singular Genomics Systems, Inc. | Methods for in situ transcriptomics and proteomics |
JP2023539360A (ja) | 2020-09-02 | 2023-09-13 | メソ スケール テクノロジーズ エルエルシー | サンプル中の1つ以上の標的分析物を検出するためのキット並びにそれを作製及び使用する方法 |
US20230349920A1 (en) | 2020-09-04 | 2023-11-02 | Meso Scale Technologies, Llc. | Methods for isolating central nervous system surface marker displaying agents |
JP2024507652A (ja) | 2021-01-11 | 2024-02-21 | メソ スケール テクノロジーズ エルエルシー | アッセイシステムの較正システム及び方法 |
EP4302089A1 (en) | 2021-03-01 | 2024-01-10 | Meso Scale Technologies, LLC | System and method for conducting a multiplexed assay |
EP4330672A1 (en) | 2021-04-26 | 2024-03-06 | Meso Scale Technologies, LLC. | Methods for isolating and analyzing a target analyte encapsulated by a surface marker displaying agent |
WO2022246215A1 (en) | 2021-05-21 | 2022-11-24 | Meso Scale Technologies, Llc. | Viral strain serology assays |
CN117999482A (zh) | 2021-06-28 | 2024-05-07 | 中尺度技术有限责任公司 | 用于测定信号扩增的方法、组合物和试剂盒 |
WO2023004339A1 (en) | 2021-07-21 | 2023-01-26 | Methodical Mind, Llc. | Graphical user interface system guide module |
WO2023245184A1 (en) | 2022-06-17 | 2023-12-21 | Meso Scale Technologies, Llc. | Viral strain serology assays |
US20240103002A1 (en) | 2022-09-23 | 2024-03-28 | Meso Scale Technologies, Llc. | Orthopoxvirus serology assays |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4161515A (en) | 1973-10-02 | 1979-07-17 | Syva Company | Double receptor fluorescent immunoassay |
US4604263A (en) * | 1976-06-17 | 1986-08-05 | Analytical Products, Inc. | Cell for gas sample equilibrator |
US4139346A (en) | 1977-11-28 | 1979-02-13 | Enzo Bio Chem Incorporated | Nucleic acid and protein binding paper |
FI56750C (fi) | 1978-02-27 | 1980-03-10 | Reijo Vihko | Rekationskaerl foer engaongsbruk vid immunologiskt bestaemning |
IL55816A (en) | 1978-10-30 | 1982-04-30 | Ames Yissum Ltd | Method for simultaneous immunoassay of several different antibodies and a kit therefor |
US4378344A (en) | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
US4514508A (en) | 1982-07-06 | 1985-04-30 | Biond Inc. | Assaying for a multiplicity of antigens or antibodies with a detection compound |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
AU3844485A (en) | 1984-02-09 | 1985-08-15 | Enzo Biochem Inc. | Heterologous detection of cabeled dna |
US4748111A (en) | 1984-03-12 | 1988-05-31 | Molecular Diagnostics, Inc. | Nucleic acid-protein conjugate used in immunoassay |
US5288609A (en) | 1984-04-27 | 1994-02-22 | Enzo Diagnostics, Inc. | Capture sandwich hybridization method and composition |
CA1260372A (en) | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Hybridization method for the detection of genetic materials |
US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
JPH0823558B2 (ja) | 1984-11-27 | 1996-03-06 | オ−ジエニクス リミテツド | 検定装置 |
JPH076984B2 (ja) | 1985-05-31 | 1995-01-30 | 株式会社日立製作所 | 複数項目分析方法 |
US5147806A (en) | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
US5591581A (en) | 1986-04-30 | 1997-01-07 | Igen, Inc. | Electrochemiluminescent rhenium moieties and methods for their use |
US6165729A (en) | 1986-04-30 | 2000-12-26 | Hyperion Catalysis International, Inc. | Electrochemiluminescent reaction utilizing amine-derived reductant |
US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
US5750338A (en) | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
US4870003A (en) | 1987-06-15 | 1989-09-26 | Coulter Corporation | Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
US5308754A (en) | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
US5354655A (en) | 1988-03-29 | 1994-10-11 | Biocontrol Systems, Inc. | Method for determining the presence or concentration of a bound enzyme |
US5093268A (en) | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
US6448091B1 (en) | 1988-11-03 | 2002-09-10 | Igen International, Inc. | Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection |
US5705402A (en) | 1988-11-03 | 1998-01-06 | Igen International, Inc. | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
ES2088427T3 (es) | 1989-03-21 | 1996-08-16 | Hygeia Sciences Ltd | Ensayo simultaneo de dos analitos. |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
CA2022518A1 (en) | 1989-08-04 | 1991-02-05 | Richard P. Watts | Heterogeneous binding assays |
US5719063A (en) | 1989-08-25 | 1998-02-17 | Boehringer Mannheim Corporation | Multiplex immunoassay system |
US5324457A (en) | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
US5629153A (en) | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
EP0515370B1 (en) | 1990-02-22 | 1995-03-01 | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING (McGILL UNIVERSITY) | A solid-phase interferometric immunoassay system |
US5143852A (en) | 1990-09-14 | 1992-09-01 | Biosite Diagnostics, Inc. | Antibodies to ligand analogues and their utility in ligand-receptor assays |
US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
US5726064A (en) | 1990-11-22 | 1998-03-10 | Applied Research Systems Ars Holding Nv | Method of assay having calibration within the assay |
ZA92803B (en) | 1991-02-06 | 1992-11-25 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescene asay including plurality of magnets |
JPH0534345A (ja) | 1991-02-19 | 1993-02-09 | Tdk Corp | 化学発光を利用する抗原・抗体の測定方法 |
US5877028A (en) | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
EP0594763B1 (en) | 1991-07-16 | 1998-09-23 | Transmed Biotech Incorporated | Methods and compositions for simultaneous analysis of multiple analytes |
CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
EP0608370B1 (en) | 1991-10-15 | 1998-01-07 | Multilyte Limited | Binding assay employing labelled reagent |
ZA929351B (en) | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5518887A (en) | 1992-03-30 | 1996-05-21 | Abbott Laboratories | Immunoassays empolying generic anti-hapten antibodies and materials for use therein |
US5795714A (en) | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
US6087491A (en) * | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
IT1270951B (it) | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma |
US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
US5789167A (en) * | 1993-09-10 | 1998-08-04 | Genevue, Inc. | Optical detection of position of oligonucleotides on large DNA molecules |
US5415839A (en) | 1993-10-21 | 1995-05-16 | Abbott Laboratories | Apparatus and method for amplifying and detecting target nucleic acids |
US5561043A (en) | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US7569341B2 (en) | 1994-01-31 | 2009-08-04 | Trustees Of Boston University | Nucleic acid directed immobilization arrays and methods of assembly |
US5786141A (en) | 1994-08-26 | 1998-07-28 | Bard; Allen J. | Electrogenerated chemiluminescence labels for analysis and/or referencing |
US5648213A (en) | 1994-08-30 | 1997-07-15 | Beckman Instruments, Inc. | Compositions and methods for use in detection of analytes |
US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
US5866434A (en) | 1994-12-08 | 1999-02-02 | Meso Scale Technology | Graphitic nanotubes in luminescence assays |
US5643713A (en) | 1995-06-07 | 1997-07-01 | Liang; Pam | Electrochemiluminescent monitoring of compounds |
US5641623A (en) | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
CN1192097C (zh) * | 1995-03-10 | 2005-03-09 | 梅索磅秤技术有限公司 | 多阵列、多特异性的电化学发光检验 |
US6207369B1 (en) | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US5722553A (en) * | 1995-03-31 | 1998-03-03 | Hovatter; Kenneth P. | Integral assembly of microcentrifuge strip tubes having independently tethered angularly related seal caps |
US5679519A (en) | 1995-05-09 | 1997-10-21 | Oprandy; John J. | Multi-label complex for enhanced sensitivity in electrochemiluminescence assay |
US6319670B1 (en) | 1995-05-09 | 2001-11-20 | Meso Scale Technology Llp | Methods and apparatus for improved luminescence assays using microparticles |
US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
US5723320A (en) | 1995-08-29 | 1998-03-03 | Dehlinger; Peter J. | Position-addressable polynucleotide arrays |
EP0852004B1 (en) | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
GB9606850D0 (en) | 1996-04-01 | 1996-06-05 | Univ Liverpool | An assay system and novel labelled compounds for use therwith |
US6001310A (en) * | 1996-10-11 | 1999-12-14 | Shaffer; John V. | Pliable centrifuge tube array |
CA2274315A1 (en) * | 1996-12-06 | 1998-06-11 | Niels Pallisgaard | Detection of chromosomal abnormalities |
FR2764381A1 (fr) | 1997-06-09 | 1998-12-11 | Univ De Neuchatel | Detecteur electrochimioluminescent |
US6413783B1 (en) | 1997-09-18 | 2002-07-02 | Meso Scale Technologies, Llc | Assay sonication apparatus and methodology |
US6200531B1 (en) | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
EP0962773A1 (en) | 1998-06-03 | 1999-12-08 | Mark Howard Jones | Electrochemical based assay processes instrument and labels |
GB9815042D0 (en) | 1998-07-10 | 1998-09-09 | Imperial College | Detector |
US6214552B1 (en) | 1998-09-17 | 2001-04-10 | Igen International, Inc. | Assays for measuring nucleic acid damaging activities |
WO2000031536A2 (en) * | 1998-11-23 | 2000-06-02 | President And Fellows Of Harvard College | Detecting structural or synthetic information about chemical compounds |
US6136268A (en) | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
US20050287592A1 (en) * | 2000-08-29 | 2005-12-29 | Yeda Research And Development Co. Ltd. | Template-dependent nucleic acid polymerization using oligonucleotide triphosphates building blocks |
US7070740B1 (en) | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
US6601725B2 (en) * | 2001-05-15 | 2003-08-05 | 3088081 Canada, Inc. | Integral assembly of reagent tubes and seal caps |
EP2420824B1 (en) | 2001-06-29 | 2018-11-28 | Meso Scale Technologies LLC | Multi-well plate having an array of wells and kit for use in the conduct of an ECL assay |
US6942972B2 (en) | 2001-10-24 | 2005-09-13 | Beckman Coulter, Inc. | Efficient synthesis of protein-oligonucleotide conjugates |
AU2003263937B2 (en) * | 2002-08-19 | 2010-04-01 | The President And Fellows Of Harvard College | Evolving new molecular function |
US20040049351A1 (en) | 2002-08-28 | 2004-03-11 | Matson Robert S. | Immunosorbent assay in microarray format |
US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
US7229763B2 (en) | 2003-04-07 | 2007-06-12 | Beckman Coulter, Inc. | Assay system using labeled oligonucleotides |
US7195875B2 (en) | 2003-04-18 | 2007-03-27 | Beckman Coulter, Inc. | Oligonucleotide pairs for multiplexed binding assays |
US20040258563A1 (en) * | 2003-06-23 | 2004-12-23 | Applera Corporation | Caps for sample wells and microcards for biological materials |
JP2005164509A (ja) * | 2003-12-05 | 2005-06-23 | Hitachi High-Technologies Corp | 試薬容器 |
JP2007525661A (ja) * | 2003-12-12 | 2007-09-06 | セントルイス ユニバーシティー | 大分子その他の分析物の検出用生物センサー |
CA2565967A1 (en) | 2004-06-10 | 2005-12-29 | Perkinelmer Las, Inc. | Multiplexing assays for analyte detection |
US7704730B2 (en) * | 2004-10-14 | 2010-04-27 | Meso Scale Technologies, Llc | Multiplexed assay methods |
US20060292559A1 (en) | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
US7494776B2 (en) | 2005-07-07 | 2009-02-24 | Beckman Coulter, Inc. | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands |
KR100927886B1 (ko) | 2007-06-18 | 2009-11-23 | 한국생명공학연구원 | 단백질 g-올리고 뉴클레오타이드 결합체 |
US8324372B2 (en) * | 2007-07-13 | 2012-12-04 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
EP2167634A4 (en) | 2007-07-16 | 2013-11-06 | California Inst Of Techn | NETWORKS, SUBSTRATES, DEVICES, METHODS AND SYSTEMS FOR DETECTION OF TARGET MOLECULES |
CN101952719A (zh) * | 2007-07-27 | 2011-01-19 | 通信改革公司 | 检测测定法及其用途 |
EP2088204A1 (en) | 2008-02-05 | 2009-08-12 | Adnagen AG | Method and kit for diagnosing or controlling the treatment of ovarian cancer |
JP2011527903A (ja) | 2008-07-14 | 2011-11-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 細胞マイクロキャリアのアセンブリを供給するためのプロセス |
CA2647953A1 (en) * | 2008-12-29 | 2010-06-29 | Sqi Diagnostics Systems Inc. | Multiplex analyte detection |
US20100261292A1 (en) * | 2009-04-10 | 2010-10-14 | Meso Scale Technologies, Llc | Methods for Conducting Assays |
US8480953B2 (en) * | 2009-05-20 | 2013-07-09 | Protedyne Corporation | System and method for vessel alignment |
US20130123121A1 (en) * | 2010-11-22 | 2013-05-16 | The University Of Chicago | Methods and/or Use of Oligonucleotide-Bead Conjugates for Assays and Detections |
US9182334B2 (en) * | 2012-02-24 | 2015-11-10 | Agilent Technologies, Inc. | Method of determining thermodynamic and kinetic parameters from measured off rates |
JP5926990B2 (ja) * | 2012-03-16 | 2016-05-25 | シスメックス株式会社 | 検体処理装置 |
US9180461B2 (en) * | 2012-10-22 | 2015-11-10 | Qiagen Gaithersburg, Inc. | Condensation-reducing incubation cover |
USD703345S1 (en) * | 2012-10-29 | 2014-04-22 | Universal Bio Research Co., Ltd. | Plurality of reaction vessels with lids |
MX2015009264A (es) * | 2013-01-18 | 2016-03-31 | Biomeme Inc | Dispositivo analitico. |
CA3153763A1 (en) * | 2013-03-11 | 2014-10-09 | Meso Scale Technologies, Llc. | Improved methods for conducting multiplexed assays |
US9802196B2 (en) * | 2013-03-13 | 2017-10-31 | Alphagem Bio Inc. | Ergonomic numbered connector to hold tubes with improved cap |
CN112831410A (zh) * | 2013-03-15 | 2021-05-25 | 伯克顿迪金森公司 | 过程管和承载托盘 |
US8808650B1 (en) * | 2013-03-15 | 2014-08-19 | Shazi Iqbal | Foldable specimen rack with configurable specimen receiver |
EP3696277B1 (en) * | 2013-07-30 | 2023-01-25 | President and Fellows of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
-
2014
- 2014-03-11 CA CA3153763A patent/CA3153763A1/en active Pending
- 2014-03-11 US US14/203,638 patent/US10189023B2/en active Active
- 2014-03-11 AU AU2014249190A patent/AU2014249190C1/en active Active
- 2014-03-11 EP EP14778374.0A patent/EP2972353B1/en active Active
- 2014-03-11 KR KR1020227036862A patent/KR20220147717A/ko not_active Application Discontinuation
- 2014-03-11 EP EP23157850.1A patent/EP4219750A3/en active Pending
- 2014-03-11 ES ES14778374T patent/ES2942031T3/es active Active
- 2014-03-11 KR KR1020217020789A patent/KR102459433B1/ko active IP Right Grant
- 2014-03-11 KR KR1020157028300A patent/KR102275006B1/ko active IP Right Grant
- 2014-03-11 DK DK14778374.0T patent/DK2972353T3/da active
- 2014-03-11 WO PCT/US2014/022948 patent/WO2014164594A1/en active Application Filing
- 2014-03-11 CA CA2904020A patent/CA2904020C/en active Active
- 2014-03-11 CN CN201910389701.1A patent/CN110286215A/zh active Pending
- 2014-03-11 CN CN201480026770.1A patent/CN105378477B9/zh active Active
- 2014-03-11 JP JP2016501106A patent/JP6791750B2/ja active Active
-
2015
- 2015-09-08 US US14/847,761 patent/US20160069872A1/en not_active Abandoned
- 2015-09-08 US US14/847,381 patent/US10413904B2/en active Active
-
2016
- 2016-01-25 HK HK16100792.2A patent/HK1213048A1/zh unknown
-
2017
- 2017-10-16 US US15/784,399 patent/US10201812B2/en not_active Ceased
-
2018
- 2018-12-05 US US16/210,165 patent/US11148145B2/en active Active
- 2018-12-20 US US16/227,081 patent/US11059046B2/en active Active
-
2019
- 2019-09-13 US US16/570,309 patent/US11772098B2/en active Active
-
2020
- 2020-01-30 AU AU2020200675A patent/AU2020200675B2/en active Active
-
2021
- 2021-02-11 US US17/173,898 patent/USRE49774E1/en active Active
- 2021-03-29 US US17/215,962 patent/US11951483B2/en active Active
- 2021-09-16 US US17/476,880 patent/US20210402390A1/en active Pending
-
2022
- 2022-09-19 AU AU2022233771A patent/AU2022233771A1/en active Pending
-
2023
- 2023-08-24 US US18/237,677 patent/US20240042447A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6791750B2 (ja) | 多重化アッセイを行うための改良された方法 | |
US20220033918A1 (en) | Co-binder assisted assay methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170131 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170131 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200305 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200717 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200720 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200825 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200831 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200901 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6791750 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |